Satellos Bioscience Inc. - Asset Resilience Ratio
Satellos Bioscience Inc. (MSCL) has an Asset Resilience Ratio of 68.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MSCL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Satellos Bioscience Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MSCL total asset value.
Liquid Assets Composition Over Time
This chart breaks down Satellos Bioscience Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore MSCL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$51.25 Million | 68.08% |
| Total Liquid Assets | CA$51.25 Million | 68.08% |
Asset Resilience Insights
- Very High Liquidity: Satellos Bioscience Inc. maintains exceptional liquid asset reserves at 68.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Satellos Bioscience Inc. Industry Peers by Asset Resilience Ratio
Compare Satellos Bioscience Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Satellos Bioscience Inc. (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Satellos Bioscience Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.95% | CA$27.68 Million ≈ $20.02 Million |
CA$31.83 Million ≈ $23.03 Million |
+15.37pp |
| 2024-12-31 | 71.58% | CA$52.27 Million ≈ $37.81 Million |
CA$73.02 Million ≈ $52.82 Million |
-4.20pp |
| 2023-12-31 | 75.78% | CA$33.57 Million ≈ $24.28 Million |
CA$44.30 Million ≈ $32.04 Million |
+53.21pp |
| 2022-12-31 | 22.57% | CA$1.40 Million ≈ $1.01 Million |
CA$6.20 Million ≈ $4.48 Million |
+3.79pp |
| 2021-12-31 | 18.78% | CA$2.36 Million ≈ $1.71 Million |
CA$12.59 Million ≈ $9.10 Million |
-7.56pp |
| 2015-12-31 | 26.34% | CA$1.03 Million ≈ $742.41K |
CA$3.90 Million ≈ $2.82 Million |
-2.11pp |
| 2014-12-31 | 28.45% | CA$2.02 Million ≈ $1.46 Million |
CA$7.09 Million ≈ $5.13 Million |
+8.12pp |
| 2013-12-31 | 20.33% | CA$799.43K ≈ $578.30K |
CA$3.93 Million ≈ $2.84 Million |
-1.60pp |
| 2012-12-31 | 21.93% | CA$660.62K ≈ $477.88K |
CA$3.01 Million ≈ $2.18 Million |
-14.42pp |
| 2011-12-31 | 36.35% | CA$1.07 Million ≈ $774.25K |
CA$2.94 Million ≈ $2.13 Million |
-16.22pp |
| 2010-12-31 | 52.57% | CA$1.41 Million ≈ $1.02 Million |
CA$2.68 Million ≈ $1.94 Million |
-1.69pp |
| 2009-12-31 | 54.26% | CA$2.50 Million ≈ $1.81 Million |
CA$4.62 Million ≈ $3.34 Million |
+52.97pp |
| 2007-12-31 | 1.29% | CA$42.10K ≈ $30.46K |
CA$3.27 Million ≈ $2.37 Million |
-- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more